Using de-identified data for 53 million unique cardiovascular patients, the report examines prevalence across all 50 states and a variety of demographics
.
Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.